Skeletal Muscle Relaxants
High-yield Verified · Jul 2026Prototype: cyclobenzaprine
Two families: antispasmodics for acute painful spasm (cyclobenzaprine, methocarbamol, carisoprodol, tizanidine) and antispastics for chronic spasticity (baclofen, dantrolene, diazepam). No shared stem.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Two problems, two families of relaxant
The name "muscle relaxant" hides two very different clinical problems. Antispasmodics treat acute, painful muscle spasm — the classic "threw my back out" strain — as a short-term adjunct to rest and physical therapy. Antispastics treat spasticity, the chronic, velocity-dependent stiffness that comes from an upper-motor-neuron injury — multiple sclerosis, cerebral palsy, spinal-cord injury, stroke — where the goal is ongoing function, not a two-week course. Sorting a drug into the right family tells you how it’s used and how long.
Here is the crucial mechanistic truth about the antispasmodics: most of them don’t act on muscle at all. Cyclobenzaprine, methocarbamol, carisoprodol, and metaxalone are central nervous system depressants whose "relaxation" is largely generalized sedation damping down spinal reflex activity — their exact mechanisms are poorly defined. Cyclobenzaprine is even structurally a tricyclic antidepressant, which is why it carries anticholinergic baggage. The antispastics are more targeted: baclofen is a GABA-B agonist in the spinal cord; diazepam works through GABA-A; tizanidine is a central alpha-2 agonist (like clonidine). And one drug stands apart entirely — dantrolene — which we’ll come to.
02 The class danger — sedation, falls, and additive depression
Because so many of these drugs work by sedating the brain, the defining class effect is exactly that: drowsiness, dizziness, and weakness — a direct fall risk, especially in older adults (the AGS Beers Criteria flag muscle relaxants as poorly tolerated in the elderly: sedation, anticholinergic effects, and fractures, with questionable benefit). This is why they are meant for short-term use (cyclobenzaprine only 2–3 weeks), why patients are told not to drive until they know the effect, and why fall precautions are routine.
The single most important safety concept is additive CNS depression. Stack a muscle relaxant on top of an opioid, a benzodiazepine, or alcohol, and the sedation compounds — the FDA warns this combination can cause profound sedation, respiratory depression, and death. The muscle relaxant isn’t usually the headline drug in that warning, but it is a potent contributor. So the nurse’s reflex is to scan the whole medication list for other depressants before giving one, and to teach patients not to add alcohol. One agent raises the stakes further: carisoprodol (Soma) is metabolized to meprobamate and is a Schedule IV controlled substance with real abuse, dependence, and withdrawal potential.
03 The agent-specific traps — and dantrolene, the exception
Beyond the shared sedation, several agents carry specific dangers worth memorizing. Cyclobenzaprine, being a tricyclic, brings anticholinergic effects (dry mouth, urinary retention, blurred vision) and is contraindicated within 14 days of an MAO inhibitor (hyperpyretic crisis, seizures, death), in the acute recovery phase of MI, and with arrhythmias/heart block or hyperthyroidism. Tizanidine can drop blood pressure (alpha-2 agonist), needs liver-enzyme monitoring, and is contraindicated with the CYP1A2 inhibitors ciprofloxacin and fluvoxamine, which raise its level enormously (up to 30-fold) → dangerous hypotension and sedation. Baclofen must never be stopped abruptly — and intrathecal baclofen (delivered by an implanted pump) carries a boxed warning: sudden withdrawal (a failed pump, empty reservoir) causes high fever, altered mental status, and rebound spasticity that can progress to rhabdomyolysis, multi-organ failure, and death — a true emergency.
Then there is dantrolene, the exception that proves the rule. Unlike every other agent here, it acts directly on skeletal muscle, blocking the ryanodine receptor so the sarcoplasmic reticulum releases less calcium — it uncouples excitation from contraction without sedating the brain. That unique action makes it the specific antidote for malignant hyperthermia (the runaway hypermetabolic crisis triggered by certain anesthetics) and useful in neuroleptic malignant syndrome. Its price is the liver: oral dantrolene carries a boxed warning for hepatotoxicity, so liver function is checked before and during therapy. (Tizanidine and metaxalone also warrant liver awareness.)
Drug names
Indications
- Acute, painful musculoskeletal spasm — short-term adjunct to rest/PT (antispasmodics)
- Chronic spasticity from upper-motor-neuron disorders — MS, cerebral palsy, spinal-cord injury, stroke (antispastics)
- Malignant hyperthermia and neuroleptic malignant syndrome (dantrolene)
Mechanism of action
Most skeletal muscle relaxants are centrally acting CNS depressants whose muscle-relaxant effect comes largely from sedation and reduced polysynaptic spinal reflex activity (cyclobenzaprine — a tricyclic-related agent; methocarbamol; carisoprodol; metaxalone). The antispastics act more specifically: baclofen is a spinal GABA-B agonist, diazepam a GABA-A potentiator, and tizanidine a central alpha-2 agonist. Dantrolene is the exception — it acts directly on skeletal muscle at the ryanodine receptor to reduce sarcoplasmic-reticulum calcium release, uncoupling excitation from contraction without central sedation.
Therapeutic effects — what you'll see working
The aim is enough relief of spasm or spasticity to move, sleep, and participate in therapy — not sedation for its own sake. Judge success by reduced spasm/stiffness and better function, using the lowest effective dose for the shortest appropriate time.
- Relief of acute muscle spasm
- Antispasmodics reduce the painful, involuntary spasm of an acute strain, easing pain and letting the patient rest and engage in physical therapy — a short-term benefit judged by comfort and mobility.
- Reduced spasticity & improved function
- Antispastics (baclofen, tizanidine) lower the chronic stiffness of upper-motor-neuron disorders, improving range of motion, easing care, and reducing painful spasms — judged over time by tone, function, and comfort.
- Abort a malignant-hyperthermia crisis (dantrolene)
- By blocking ryanodine-receptor calcium release, IV dantrolene halts the runaway muscle contraction and heat production of malignant hyperthermia — success is a falling temperature and resolving rigidity/metabolic derangement.
Adverse effects
The common thread is sedation and its fall risk, made dangerous by additive depressants. Layer on the agent-specific hazards: carisoprodol dependence, cyclobenzaprine’s TCA/MAOI issues, tizanidine’s hypotension/CYP1A2, baclofen withdrawal, and dantrolene/tizanidine hepatotoxicity.
Interactions
Contraindications
The safety work is avoiding additive depressants and falls, never stopping baclofen abruptly, and honoring the agent-specific bars (MAOIs with cyclobenzaprine, ciprofloxacin/fluvoxamine with tizanidine, hepatic disease with dantrolene).
When to hold
Assess before giving — these findings mean hold the dose and act.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Sources
- Cyclobenzaprine — tricyclic relation, MAOI/cardiac contraindications, serotonin syndrome (FDA label) — FDA / DailyMed
- Baclofen (intrathecal) — boxed warning on abrupt-withdrawal syndrome (FDA label) — FDA / DailyMed
- Dantrium (dantrolene) — oral hepatotoxicity boxed warning, ryanodine-receptor mechanism, malignant hyperthermia (FDA label) — FDA / DailyMed
- Skeletal muscle relaxants (methocarbamol) — antispasmodic vs antispastic, sedation & additive depression — StatPearls (NCBI)
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.